Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
about
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature ReviewMarkers of resistance to anti-EGFR therapy in colorectal cancerMolecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary fieldNew therapeutic strategies for BRAF mutant colorectal cancersPrecision medicine in colorectal cancer: the molecular profile alters treatment strategiesDiscovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiologyBRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.Mechanisms of resistance to anti-EGFR therapy in colorectal cancerAspirin use, tumor PIK3CA mutation, and colorectal-cancer survivalOncogenic mutations of PIK3CA in human cancersBRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implicationsThe epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic fluxPI3K pathway alterations in cancer: variations on a themeDifferential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.MAP kinase genes and colon and rectal cancer.Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinomaPhase II trial of gefitinib and everolimus in advanced non-small cell lung cancerPI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.Intravital imaging of mouse colonic adenoma using MMP-based molecular probes with multi-channel fluorescence endoscopyEGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancerPrimary and acquired resistance to biologic therapies in gastrointestinal cancers.Distinct molecular features of different macroscopic subtypes of colorectal neoplasmsNRAS mutations are rare in colorectal cancer.Genomic and biological characterization of exon 4 KRAS mutations in human cancerPrognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.KRAS and BRAF mutational status in colon cancer from Albanian patients.KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.Microsatellite instability in colorectal cancer-the stable evidence.High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancerImpact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detectionMutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valueMutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.Molecular alterations associated with liver metastases development in colorectal cancer patientsMultiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry
P2860
Q21142734-F411EE57-29F3-4EFA-986C-7034F34E1253Q24289005-B3ACD75D-0C79-490F-AED7-D5FD02ACBCE5Q24598640-31EEF512-88FE-429D-B9A2-B18369EB5372Q24620628-943EB07D-F709-450C-A7D8-EDF8A5A20267Q26772277-D5CB1729-9CE9-41F4-953A-3D61131D9A9EQ26795558-96EB71D7-7C2C-4984-8942-532DBFB16942Q27011884-FEBF3EF4-D7EF-4999-85BB-25740243FA83Q27852942-3B6CF578-EF60-4E73-9E10-97B052A774D6Q27853074-BD654288-7974-4773-928B-B59CC2CED6C0Q28074073-CE9D98DA-1A62-4D47-8A65-B4FFDD1867DBQ28277824-A8AF8229-795A-48C1-BBB8-72126AD2A275Q28284802-639DFD61-855A-476F-BBE5-6200FB3C4AA6Q28543370-24953358-1CC4-4F35-8411-17AC3FBEF86EQ28607006-681961FE-547A-4DF6-8CBD-EE6EA0A64217Q29615530-B67B2502-7F37-4F26-A8FF-7F952C1151AAQ30492318-B829D27C-5717-49BE-BC4A-42E4F6C5C600Q30528832-08DCBF75-07DB-484A-9278-550CBF1E4941Q33526301-CD1339F6-1902-4B0F-9F37-3B7D2698A24AQ33541323-27FC2AE3-5047-4D61-A9D4-F259F5FF0124Q33598317-FCF9B372-68D2-40AE-8662-42DFC83F60E1Q33608491-CCD90448-5299-4AAF-9DA0-360F43FB0F4EQ33618754-CFEC68FF-4AC8-4507-8BFC-D1D38F6DB660Q33634587-18B3AEDF-F3D1-4018-A4A9-3A7474299B58Q33856378-C8497654-268D-4F41-8A17-3D7AAE462D46Q33895573-20064EB4-030E-4871-8AFB-BCA80DA904AEQ34004693-FE174E2C-D077-4371-AF90-CD7162085580Q34091172-B5889FE3-A43C-4131-98B5-A250E10271A5Q34145806-105034B5-ACE1-4F55-8F17-9F9C852A480AQ34217637-9C7FE55A-3A9A-466F-8B69-C377189BB271Q34239801-FD899D3F-7F57-4EE6-AD4C-FCE07D37722AQ34346064-B4525D2C-45A2-4C74-AA1B-483F9AC7A4CDQ34509268-63230282-CE3D-451D-ACCC-C927EB6BEA80Q34616565-93F5AB67-C424-4893-9B35-3110E8A4D26CQ34645477-4CB89D1E-7156-4AE8-9532-DEB2DEEF3B24Q34687101-77E1EDE9-C14F-4D28-8B58-D72CF8D16D2AQ34720913-B4D43542-AFD5-4405-9A1C-575899E9DF70Q34755943-8A557500-E9AB-46BB-9251-4B7A3FA910B7Q34976598-9BFE3022-3B7C-4902-B22A-525346E84DB5Q35125605-E1E49430-F4B7-4ADD-BFE0-D2111215E451Q35169273-EFCDBFDF-E394-44F4-9CDE-CE679FBD0AD8
P2860
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Mutations in the RAS-MAPK, PI( ...... based series of colon cancers.
@en
Mutations in the RAS-MAPK, PI( ...... based series of colon cancers.
@nl
type
label
Mutations in the RAS-MAPK, PI( ...... based series of colon cancers.
@en
Mutations in the RAS-MAPK, PI( ...... based series of colon cancers.
@nl
prefLabel
Mutations in the RAS-MAPK, PI( ...... based series of colon cancers.
@en
Mutations in the RAS-MAPK, PI( ...... based series of colon cancers.
@nl
P2093
P356
P1476
Mutations in the RAS-MAPK, PI( ...... based series of colon cancers.
@en
P2093
Anne-Marie Bouvier
Astrid Lièvre
Caroline Chapusot
Delphine Lecorre
Francoise Piard
Jean Faivre
Jean-Marc Ferraz
Marion Cortet
Nicolas Veyrie
Patrick Rat
P304
P356
10.1002/IJC.23388
P577
2008-05-01T00:00:00Z